Proteome Sciences(DE:PI2)
€0.03+0.02 (+230.00%)
DE:PI2
Proteome Sciences financials statements
€0.03
At close:+0.02 (+230.00%)
Proteome Sciences (PI2) Ratios
0 Followers
Proteome Sciences Ratios
DE:PI2's free cash flow for Q2 2026 was £-445.00K. For the 2026 fiscal year, DE:PI2's free cash flow was decreased by £-19.00K and operating cash flow was £-426.00K. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.13 | 0.18 | 0.33 | 0.55 | 0.39 |
| Quick Ratio | 0.09 | 0.13 | 0.27 | 0.48 | 0.30 |
| Cash Ratio | 0.05 | 0.08 | 0.16 | 0.32 | 0.20 |
| Solvency Ratio | -0.12 | -0.16 | -0.13 | 0.13 | 0.02 |
| Operating Cash Flow Ratio | -0.00 | -0.06 | -0.04 | 310.83 | 897.86 |
| Short-Term Operating Cash Flow Coverage | -0.00 | -0.07 | -0.04 | 344.70 | 972.01 |
| Net Current Asset Value | £ -15.71M | £ -13.13M | £ -10.36M | £ -6.38M | £ -8.26M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 1.91 | 1.58 | 1.18 | 0.96 | 1.16 |
| Debt-to-Equity Ratio | -1.65 | -2.23 | -4.39 | -14.13 | -4.21 |
| Debt-to-Capital Ratio | 2.53 | 1.81 | 1.29 | 1.08 | 1.31 |
| Long-Term Debt-to-Capital Ratio | 0.00 | -0.04 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | -0.87 | -1.41 | -3.74 | -14.75 | -3.62 |
| Debt Service Coverage Ratio | -0.08 | -0.12 | -0.10 | 0.19 | 0.05 |
| Interest Coverage Ratio | -2.88 | -2.54 | -2.03 | 3.65 | 1.40 |
| Debt to Market Cap | 1.96 | 1.28 | 0.84 | 1.04 | 0.58 |
| Interest Debt Per Share | 0.06 | 0.05 | 0.05 | 0.04 | 0.03 |
| Net Debt to EBITDA | -8.61 | -8.84 | -10.07 | 3.73 | 14.88 |
| Profitability Margins | |||||
| Gross Profit Margin | -26.81% | -3.42% | 32.76% | 0.02% | 0.01% |
| EBIT Margin | -70.98% | -48.15% | -32.24% | 0.01% | 0.00% |
| EBITDA Margin | -46.33% | -31.02% | -22.61% | 0.01% | 0.00% |
| Operating Profit Margin | -70.98% | -46.53% | -32.24% | 0.01% | 0.00% |
| Pretax Profit Margin | -95.61% | -66.46% | -48.09% | 0.01% | 0.00% |
| Net Profit Margin | -81.50% | -69.70% | -48.59% | 0.01% | 0.00% |
| Continuous Operations Profit Margin | -81.50% | -69.70% | -48.59% | 0.01% | 0.00% |
| Net Income Per EBT | 85.24% | 104.86% | 101.03% | 105.58% | 61.02% |
| EBT Per EBIT | 134.70% | 142.83% | 149.17% | 72.63% | 28.64% |
| Return on Assets (ROA) | -37.08% | -36.99% | -21.32% | 10.66% | 0.72% |
| Return on Equity (ROE) | 32.12% | 52.27% | 79.68% | -157.18% | -2.59% |
| Return on Capital Employed (ROCE) | 32.06% | 47.33% | 159.55% | -3085.71% | -24.61% |
| Return on Invested Capital (ROIC) | -34.27% | -26.98% | -14.97% | 15.02% | 2.67% |
| Return on Tangible Assets | -75.82% | -68.27% | -33.74% | 16.13% | 1.24% |
| Earnings Yield | -41.48% | -33.94% | -18.32% | 12.28% | 0.39% |
| Efficiency Ratios | |||||
| Receivables Turnover | 4.98 | 9.60 | 4.79 | 15137.76 | 24372.17 |
| Payables Turnover | 3.33 | 7.91 | 7.53 | 4.48 | 5.78 |
| Inventory Turnover | 8.87 | 6.90 | 4.04 | 3.34 | 1.99 |
| Fixed Asset Turnover | 1.91 | 2.04 | 1.63 | 18022.78 | 17803.78 |
| Asset Turnover | 0.45 | 0.53 | 0.44 | 1909.11 | 2249.18 |
| Working Capital Turnover Ratio | -0.29 | -0.50 | -0.72 | -3722.71 | -3131.83 |
| Cash Conversion Cycle | 4.76 | 44.73 | 118.11 | 27.77 | 120.00 |
| Days of Sales Outstanding | 73.27 | 38.02 | 76.22 | 0.02 | 0.01 |
| Days of Inventory Outstanding | 41.15 | 52.87 | 90.36 | 109.15 | 183.09 |
| Days of Payables Outstanding | 109.66 | 46.15 | 48.47 | 81.41 | 63.11 |
| Operating Cycle | 114.42 | 90.88 | 166.58 | 109.17 | 183.10 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.00 | -0.00 | -0.00 | 12.60 | 29.08 |
| Free Cash Flow Per Share | -0.00 | -0.00 | -0.00 | 6.93 | 24.33 |
| Dividend Paid and CapEx Coverage Ratio | -0.47 | -3.69 | -2.03 | 2.22 | 6.12 |
| Capital Expenditure Coverage Ratio | -0.47 | -3.69 | -2.03 | 2.22 | 6.12 |
| Operating Cash Flow Coverage Ratio | -0.00 | -0.06 | -0.04 | 325.81 | 900.32 |
| Operating Cash Flow to Sales Ratio | -0.01 | -0.17 | -0.10 | 0.16 | 0.47 |
| Free Cash Flow Yield | -1.94% | -10.46% | -5.38% | 19800.89% | 47468.78% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -2.40 | -2.96 | -5.46 | 8.14 | 257.54 |
| Price-to-Sales (P/S) Ratio | 1.96 | 2.05 | 2.65 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | -0.77 | -1.54 | -4.35 | -12.80 | -6.68 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -51.61 | -9.56 | -18.57 | 0.01 | 0.00 |
| Price-to-Operating Cash Flow Ratio | -160.43 | -12.15 | -27.72 | 0.00 | 0.00 |
| Price-to-Earnings Growth (PEG) Ratio | 0.25 | -0.08 | 0.02 | 0.00 | -3.22 |
| Enterprise Value Multiple | -12.86 | -15.46 | -21.80 | 8.80 | 44.55 |
| Enterprise Value | 22.37M | 23.43M | 24.78M | 18.71M | 27.84M |
| EV to EBITDA | -12.86 | -15.46 | -21.80 | 8.80 | 44.55 |
| EV to Sales | 5.96 | 4.79 | 4.93 | 0.00 | 0.00 |
| EV to Free Cash Flow | -156.42 | -22.31 | -34.52 | 0.01 | 0.00 |
| EV to Operating Cash Flow | -486.27 | -28.37 | -51.52 | 0.00 | 0.00 |
| Tangible Book Value Per Share | -0.05 | -0.04 | -0.02 | -0.02 | -0.02 |
| Shareholders’ Equity Per Share | -0.03 | -0.02 | -0.01 | -0.00 | -0.01 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.15 | -0.05 | -0.01 | -0.06 | 0.39 |
| Revenue Per Share | 0.01 | 0.02 | 0.02 | 77.01 | 62.44 |
| Net Income Per Share | -0.01 | -0.01 | -0.01 | 0.00 | 0.00 |
| Tax Burden | 0.85 | 1.05 | 1.01 | 1.06 | 0.61 |
| Interest Burden | 1.35 | 1.38 | 1.49 | 0.73 | 0.29 |
| Research & Development to Revenue | 0.00 | 0.12 | 0.13 | 0.00 | 0.00 |
| SG&A to Revenue | 0.44 | 0.31 | 0.65 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.01 | 0.04 | 0.00 | 0.00 |
| Income Quality | 0.02 | 0.24 | 0.20 | 2929.81 | 146138.89 |
Currency in GBP
